关于我们
图片名称

News

Tang xican, academician of Chinese Academy of engineering, visited wanbond pharmaceutical


On October 21, 2020, academician Tang xican of the Chinese Academy of Engineering visited wanbond pharmaceutical for investigation, guidance, discussion and exchange, accompanied by relevant personnel of Wenling Association for science and technology. Academician Tang xican went deep into the workshop to observe the product production, listened carefully to the key technologies and processes of drug production and quality management and the construction plan of new industrialization support platform in the future, and spoke highly of the enterprise's ability to improve product quality and production efficiency, promote the transformation and application of scientific and technological achievements, and improve product added value.

       

 

Academician Tang xican inspected the product production line

        

Academician Tang xican and Chen an, executive deputy general manager of wanbond pharmaceutical, exchanged product production technology 

At the symposium, Chen an, executive deputy general manager of wanbond pharmaceutical, humbly asked academician Tang for advice on the difficulties and problems encountered in the in-depth development of huperzine a project. After repeated communication, academician Tang put forward valuable opinions and suggestions on the problems in the process of project research. In addition, academician Tang also said: "In the 1980s, we kept pace with the international community in the research and development of drugs for the treatment of Alzheimer's disease. Huperzine a not only delayed Alzheimer's disease, but also played a great role in benign memory impairment. We cooperated with wanbond pharmaceutical in the research and development of huperzine A, hoping to further expand the scope of indications for the injection of the product and make it more effective The product quality has been improved to a new level. The huperzine a controlled-release tablets under research and development have also successfully entered the phase I clinical trial stage. If everything goes well, we will enter the next stage of research as soon as possible, and bring the products to the market as soon as possible to benefit the majority of patients. "
 

        

Academician Tang xican held a project discussion with executive vice president Chen an

Chen an, executive deputy general manager of wanbond pharmaceutical, introduced that at present, the company cooperates with the academician team to develop huperzine a slow-release and controlled-release preparation. The patients have changed from twice a day to once a day, and the patients have better compliance. He pointed out that due to the relationship of dose, high dose will have a great impact on peripheral cholinergic and have prominent side effects on gastrointestinal tract. After changing huperzine A into sustained-release dosage form, we will adjust the plasma drug concentration in vivo accordingly to reduce the occurrence of side effects and improve the drug efficacy.
It is understood that since wanbond pharmaceutical and academician Tang xican reached a cooperative relationship and established the "academician expert workstation" in 2015, the two sides have carried out in-depth cooperation on huperzine a project, integrated the advantageous resources of both sides and gave full play to their advantages. Up to now, with the support of academician Tang xican and his scientific research team, various preparations of huperzine A have achieved certain results. Huperzine A injection has been mass produced and sold; Huperzine a controlled-release tablets have entered phase I clinical trials. It is believed that these varieties will bring more economic benefits to the enterprise.